Another antiparasitic drug has emerged as a potential treatment for COVID-19, and trial site organization in Cullman, Alabama, called Cullman Clinical Trials, will be conducting a study to determine if this repurposed drug can be used to fight the coronavirus. This research site seeks 800 participants to test nitazoxanide and its potential to treat COVID-19. Cullman Clinical Trials is affiliated with Cullman Primary Care, and this relationship assures access to more patients than the typical independent trial site organization. Can a repurposed antiparasitic, rebranded as NT-300, reduce the impact of COVID-19? A Northern Alabama research site partners with sponsor Romark Laboratories to find out.
What is Nitazoxanide?
Produced by Romark Laboratories, this antiparasitic drug has been found to inhibit a broad range of respiratory pathogens in cell cultures, and this includes SARS-CoV-2, the virus behind COVID-19. Nitazoxanide was approved by the U.S. Food and Drug Administration (FDA) by 2002 as a treatment for diarrhea caused by the water-borne parasitic infection Cryptosporidium under the trade name Alinia.®
By April, Romark Laboratories announced the inten...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).